The Best Stocks to Invest $1,000 in Right Now

The article argues for buying beaten-down tech stocks, highlighting Palantir's revenue growth despite a 20% YTD decline, Nebius's ARR outlook of $7 billion to $9 billion this year and revenue rising from $529.8 million in 2025 to about $10 billion by 2027, and Broadcom's custom AI chips as a lower-cost alternative to Nvidia GPUs. Broadcom is also cited as up 14% YTD with a $474 consensus target implying about 19% upside. Overall, it is a bullish long-term commentary on AI-linked technology names rather than a fresh catalyst-driven news event.

Analysis

The clearest second-order read-through is that AI infrastructure is becoming a two-tier market: scarce capacity providers and lower-cost compute substitutes are taking share from pure-play GPU demand. Nebius benefits most if capacity remains the bottleneck, but that same dynamic can eventually cap pricing power as more capital chases the same colocation and power contracts; the risk is not demand collapse but margin compression once supply catches up over the next 6-12 months.

Broadcom is the more durable beneficiary than the headline suggests. Custom silicon shifts value away from raw GPU performance toward workload-specific efficiency, which matters most for hyperscalers optimizing cost per token and power usage per inference. That creates a spillover headwind for Nvidia’s premium multiple even if unit demand stays strong, because the market will start valuing AI exposure on gross margin durability rather than just revenue growth.

Palantir’s setup is more nuanced: the stock can re-rate from here if commercial adoption keeps compounding, but the next leg is likely to be driven by operating leverage in the installed base rather than more narrative expansion. The main risk is that expectations remain too elevated relative to conversion cycles in the enterprise pipeline; if budget scrutiny increases, the multiple could compress faster than fundamentals decelerate. Near term, this is a sentiment-driven name, but over a 6-18 month horizon it becomes a quality-versus-valuation debate.

The contrarian view is that the market may be underestimating how quickly AI capex diversifies away from Nvidia into custom ASIC ecosystems and how much of that spend still accrues to the enabling layer rather than the model layer. If that proves right, AVGO and NBIS can continue to outperform even if NVDA flatlines, because investors will pay for infrastructure scarcity and cost optimization before they pay for raw accelerator share.

Key Decisions for Investors

• Go long AVGO vs short NVDA in a market-neutral pair for the next 3-6 months; thesis is multiple divergence as custom ASIC adoption becomes a credible substitute for premium GPU economics. Target 8-12% relative outperformance if hyperscaler capex shifts toward efficiency.
• Buy NBIS on pullbacks for a 6-12 month horizon, but size modestly; upside is tied to capacity scarcity and guidance credibility, while downside is sharp if new supply comes online faster than expected. Use a 15-20% trailing stop because the stock is already pricing a lot of perfection.
• Initiate a tactical long PLTR only on weakness after earnings or sector selloffs; this is a momentum/quality compounder, not a cheap valuation story. Prefer call spreads over stock to limit multiple risk while keeping upside to continued commercial acceleration.
• If carrying AI beta, rotate part of NVDA exposure into AVGO rather than exiting the theme entirely; AVGO offers a better risk/reward over 6-12 months because it monetizes both custom hardware and the software/control layer around hyperscaler capex.
• For traders, consider a basket trade: long AVGO + NBIS, short NVDA, sized to neutralize broad AI factor exposure; this expresses the view that infrastructure bottlenecks and custom compute win even if the AI trade itself remains intact.